Contact Supplier

Contact Supplier

To get in touch with SIRION Biotech GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier

    .

    SIRION LentiBOOST™ non-cytotoxic transduction enhancer for lentiviral vectors

    products-servicesSIRION Biotech GmbH
    April 8th 2020

    SIRION Biotech has developed LentiBOOST as a highly effective, non-cytotoxic transduction enhancer for lentiviral vectors in preclinical and clinical applications.

    As a universally acting and receptor independent adjuvant, LentiBOOST can be applied to a wide range of clinically relevant cell types, making it a promising candidate to improve clinical transduction protocols for ex vivo gene therapies and CAR-T cell therapies.

    With up to five-fold increases in transduction, LentiBOOST offers powerful benefits for biotech and pharma companies, drug developers, academic researchers seeking improved results in CAR-T clinical trials, cell therapy research and development studies.

    LentiBOOST features

    LentiBOOST is a highly effective, non-cytotoxic transduction enhancer for preclinical and clinical application of lentiviral vectors. As universally acting (receptor independent) adjuvant it can be applied to a wide range of clinically relevant cell types including CD34+ hematopoietic stem cells (HSCs), primary T cells and NK cells.

    These unique features make it a promising candidate to improve clinical transduction protocols for ex vivo gene therapies and CAR-T cell therapies.

    LentiBOOST features include:

    • Shows up to 90% improvements in lentiviral transduction efficiency.
    • Positive impact on cell proliferation for CD34+ and T cells.
    • Non-cytotoxic.
    • Increased vector copy numbers per cell.
    • Successful track record of integration into clinical trials (III and I/II) in the US and Europe.
    • GMP batch grades available.

    LentiBOOST benefits

    LentiBOOST’s powerful features and advantages deliver a series of user benefits:

    • Increased expression levels of therapeutic protein have favorable effects on success rates of clinical trials.
    • Better-optimized and more stable transgenic cell manufacturing allows reduced cost of final product.
    • LentiBOOST exhibits strong and durable therapeutic protein expression, in line with FDA/EMA criteria for ATMPs production.
    • Proven lack of cell toxicity and prior clinical applications expedite IND filings.
    • Availability of cGMP batch grades allow direct integration into clinical programs.

    LentiBOOST variants

    LentiBOOST is available in two versions:

    • LentiBOOST Pharma grade: intended for use in preclinical research and process development only.
    • LentiBOOST GMP grade: for use in clinical stage protocols, currently included in multiple Phase III and I/II clinical trials in Europe and North America.

    Contacts

    For quotes and detailed information on LentiBOOST™ technology, contact: lentiboost@sirion-biotech.com.
    For licensing options for Clinical/Commercial Use and Development, contact: licensing@sirion-biotech.com.

    Resources

    Click on LentiBOOST Transduction Enhancer for detailed information.

    SIRION LentiBOOST™ non-cytotoxic transduction enhancer for lentiviral vectors

    Comparative demonstration showing LentiBOOST™ increases
    transduction by a factor of 5

    Contact SIRION Biotech GmbH

    Simply fill out the form below to contact SIRION Biotech GmbH now.

    Send SIRION Biotech GmbH a Message